Leerink Partnrs Has Bearish Outlook for Lantheus Q3 Earnings

Key Points

• Leerink Partners has revised its Q3 2025 earnings per share estimate for Lantheus Holdings down from $1.44 to $1.24, while the consensus for the full year is at $6.01 per share.
• Recent earnings results showed Lantheus missed analyst estimates, reporting $1.57 EPS against a consensus of $1.65 and revenues of $378.05 million, below the forecast of $389.69 million.
• Following insider sales, institutional investors own 99.06% of Lantheus stock, indicating significant confidence or strategic repositioning among large shareholders.

Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) - Investment analysts at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for Lantheus in a note issued to investors on Wednesday, August 20th. Leerink Partnrs analyst R. Ruiz now anticipates that the medical equipment provider will post earnings per share of $1.24 for the quarter, down from their prior forecast of $1.44. The consensus estimate for Lantheus' current full-year earnings is $6.01 per share.

A number of other research analysts also recently weighed in on the company. William Blair restated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Truist Financial set a $63.00 target price on Lantheus and gave the stock a "hold" rating in a research note on Monday, August 11th. JMP Securities reduced their target price on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Mizuho reduced their target price on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Lantheus has a consensus rating of "Moderate Buy" and an average price target of $105.50.

Lantheus Stock Down 1.6%

LNTH stock opened at $58.21 on Monday. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The business has a 50 day moving average price of $71.48 and a two-hundred day moving average price of $84.19. The company has a market cap of $3.96 billion, a price-to-earnings ratio of 15.48 and a beta of 0.14. Lantheus has a twelve month low of $47.25 and a twelve month high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The firm had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm's quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.80 EPS.

Institutional Trading of Lantheus

Institutional investors and hedge funds have recently modified their holdings of the business. Elevation Point Wealth Partners LLC bought a new stake in shares of Lantheus during the 2nd quarter worth $26,000. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus during the 2nd quarter worth $36,000. Signaturefd LLC lifted its position in shares of Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after buying an additional 116 shares during the last quarter. Quarry LP increased its holdings in Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock worth $48,000 after purchasing an additional 470 shares in the last quarter. Finally, Hughes Financial Services LLC bought a new position in Lantheus in the first quarter valued at about $81,000. 99.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Lantheus

In other Lantheus news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,838,066 shares of company stock valued at $384,430,031 in the last ninety days. 2.00% of the stock is currently owned by corporate insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.